BPG is committed to discovery and dissemination of knowledge
Featured Articles
4/12/2023 9:42:37 AM | Browse: 508 | Download: 1453
Publication Name World Journal of Gastrointestinal Oncology
Manuscript ID 81122
Country China
ISSN 1948-5204 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Retrospective Study
Article Title Correlation between immune-related adverse events and long-term outcomes in pembrolizumab-treated patients with unresectable hepatocellular carcinoma: A retrospective study
Manuscript Source Unsolicited Manuscript
All Author List Jiang-Min Zhou, Hui-Fang Xiong, Xiao-Ping Chen, Zhi-Wei Zhang, Li-Ping Zhu and Biao Wu
Funding Agency and Grant Number
Corresponding Author Biao Wu, MD, Doctor, Doctor, Department of Hepatobiliary Surgery, Wuhan Hospital of Traditional Chinese and Western Medicine, No. 215 Zhongshan Avenue, Qiaokou District, Wuhan 430030, Hubei Province, China. wuhanyywb@163.com
Key Words Hepatocellular carcinoma; Immune checkpoint inhibitors; Pembrolizumab; Immune-related adverse events; Overall survival; Retrospective study
Core Tip This is a retrospective study to elucidate the correlation between immune-related toxic effects and prognosis in patients with unresectable hepatocellular carcinoma (HCC) treated with pembrolizumab. One hundred and forty-three male patients and forty-seven female patients were included in the study. The overall incidence of treatment-related adverse events was 72.6% (138/190) and 10.0% of them were severe immune-related adverse events (irAEs) (grade ≥ 3). Patients with hypothyroidism were observed to have a longer overall survival and time to progression than those without irAEs. Unresectable HCC patients who experienced hypothyroidism had a better therapeutic effect.
Publish Date 2023-04-12 08:10
Citation Zhou JM, Xiong HF, Chen XP, Zhang ZW, Zhu LP, Wu B. Correlation between immune-related adverse events and long-term outcomes in pembrolizumab-treated patients with unresectable hepatocellular carcinoma: A retrospective study. World J Gastrointest Oncol 2023; 15(4): 689-699
URL https://www.wjgnet.com/1948-5204/full/v15/i4/689.htm
DOI https://dx.doi.org/10.4251/wjgo.v15.i4.689
Full Article (PDF) WJGO-15-689.pdf
Full Article (Word) WJGO-15-689.docx